This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

Connect with your local NUBEQA® (darolutamide) Representative

We are committed to supporting healthcare professionals with the resources and information they need.

Nubeqa Banner

Connect with our team for personalised support and access to resources on NUBEQA and the ARANOTE indication.

Please fill out the short form below and our team will get back to you promptly to support your requirement or to set up a convenient time for a visit.

We look forward to connecting with you soon.

Prescribing information for NUBEQA® (darolutamide) can be found here.

NUBEQA® (darolutamide) | New License Available
The only ARI approved for mHSPC with and without docetaxel, offering flexibility to tailor your treatment decisions.
PP-NUB-GB-2446, June 2025
NUBEQA® (darolutamide) Drug-Drug Interactions Learning Guide
PP-NUB-GB-2129, March 2025
NUBEQA® (darolutamide) Resources
PP-NUB-GB-2048, February 2025

PP-NUB-GB-2452 | June 2025